Entity family

Browse diseases

Named diseases, disorders, syndromes, injuries, and health conditions. Examples include epilepsy, diabetes, stroke.

23,712articles mentioning diseases

125,551disease mentions

18,081distinct diseases extracted

0%of mentions human-reviewed

Filter articles

JournalContent resourceEvidence policyAutomated confidence floorArticles per pageReset filters

“Reviewed + threshold” includes every confirmed correction plus unreviewed proposals at or above the selected model score.

All extracted diseases

Showing 11,041–11,100 of 18,081, ordered by supporting articles. Choose a disease to see its evidence.

Poststroke depression1 Poststroke depression (PSD)1 Poststroke dysphagia1 Poststroke motor dysfunction1 Postural orthostatic tachycardia syndrome (POTS)1 Potocki-Lupski syndrome1 Prader–Willi syndrome1 Pre-eclampsia12651 Pre-eclampsia3741 Pre-eclampsia4941 Precursor T-Lymphoblastic Lymphoma1 Prediabetes5381 PreeclampsiaPreeclampsia1 Preganglionic trigeminal nerve palsy (PrGTP)1 Pregnancy-related anaemia1 Pregnant women1 Premature acute coronary syndrome1 Premature coronary artery disease1 Premature ventricular complexes (PVCs)1 Preoperative anxiety1 Preprocedural ASILs1 Preterm birth (PTB)1 Primary adrenal leiomyosarcoma1 Primary and secondary cancers of the liver1 Primary bile duct lymphoma1 Primary bladder perivascular epithelioid cell tumours1 Primary central nervous system T-cell lymphoma1 Primary central nervous system lymphoma (PCNSL)1 Primary cervical lymphoma1 Primary cutaneous aspergillosis1 Primary cutaneous peripheral T-cell lymphoma1 Primary dysmenorrhoea1 Primary graft failure (PGF)1 Primary immunodeficiencies1 Primary intestinal lymphangiectasia1 Primary lung tumours1 Primary lymphoma of the bone1 Primary mucocutaneous tuberculosis1 Primary non-Hodgkin’s lymphoma1 Primary ovarian lymphoma1 Primary palmar hyperhidrosis (PPH)1 Primary postpartum haemorrhage1 Primary progressive aphasia (PPA)1 Primary pulmonary lymphoma1 Primary spinal angiosarcoma1 Primary tracheal carcinoid1 Primary urethral adenocarcinoma1 Primary uterine rupture1 Primary vulvar adenocarcinomas1 Progressive Familial lntrahepatic Cholestasis (PFIC)1 Progressive Fibrosing ILD1 Progressive Fibrosis Interstitial Lung Diseases (PFILD)1 Progressive Neurodegenerative Diseases1 Progressive SystemicSclerosis1 Progressive disease331 Progressive in-stent restenosis1 Progressive interstitial lung disease (ILD)1 Proximal basilar artery aneurysms1 Proximal tibial stress fractures (PTSFs)1 Pruritic urticarial papules and plaques of pregnancy1

View all 18,081 diseases on one page

Articles mentioning diseases

23,712 articles · page 401 of 1976

4CPS-044 Comparison of the effectiveness of atogepant combined with botulinum toxin versus atogepant monotherapy in the prevention of chronic migraine

ejhpharm · abstract · 2026-03-18 · 7 matching annotations

98.9%

chronic migraine CM atogepant BTX-ATO ATOm

…elevance Results suggest that the effectiveness of atogepant in chronic migraine, in terms of reducing monthly migraine days, is comparable betw…

4CPS-077 Effectiveness of faricimab treatment: real-world study in a tertiary hospital

ejhpharm · abstract · 2026-03-18 · 7 matching annotations

97.5%

diabetic macular oedema neovascular age-related macular degeneration nAMD DME faricimab ranibizumab aflibercept brolucizumab

…ment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME). Unlike previous anti-VEGF agents, faricimab targets both…

4CPS-096 The impact of pharmaceutical interventions on the management of hospitalised patients with cirrhosis: what role does the clinical pharmacist play?

ejhpharm · abstract · 2026-03-18 · 7 matching annotations

95.4%

hepatic impairment cirrhosis hepatic insufficiency beta-blockers secondary care hospital psycholeptics hypolipidemic agents Society of Hospital Pharmacists of Australia

…y, is limited. The adaptation of drug dosages in the context of hepatic impairment is a complex issue that lacks comprehensive discussion in curre…

4CPS-124 Off-label use of dalbavancin in real-world clinical practice: a retrospective observational study

ejhpharm · abstract · 2026-03-18 · 7 matching annotations

94.8%

ABSSSI osteomyelitis spondylodiscitis acute bacterial skin and skin structure infections prosthetic joint infection complex infections dalbavancin Ambulatory consolidation therapy Hospital Pharmacy Department

…odality. Off-label use was defined as any indication other than ABSSSI. A stepwise backward selection linear regression model was used…

4CPS-140 Off-label use of sodium zirconium cyclosilicate in acute severe hyperkalaemia: evaluation of use conditions and effectiveness

ejhpharm · abstract · 2026-03-18 · 7 matching annotations

96.7%

acute severe hyperkalaemia chronic hyperkalaemia acute hyperkalaemia renal failure calcium gluconate insulin intravenous glucose SZC tertiary hospital

…tiation.SZC appears to be an effective adjunctive treatment for acute severe hyperkalaemia in patients with renal failure who are already receiving standa…

4CPS-148 Effectiveness and safety of atogepant in the preventive treatment of migraine

ejhpharm · abstract · 2026-03-18 · 7 matching annotations

93.0%

migraine episodic migraine atogepant

…ly approved oral calcitonin gene-related peptide antagonist for migraine prophylaxis in adults. Real-world data on its efficacy and safe…

4CPS-162 Real-world evidence with ofatumumab in multiple sclerosis

ejhpharm · abstract · 2026-03-18 · 7 matching annotations

97.4%

multiple sclerosis MS SPMS RRMS ofatumumab ocrelizumab teriflunomide natalizumab

… all patients with relapsing-remitting or secondary progressive multiple sclerosis (RRMS; SPMS), who initiated Ofatumumab between January 2023 and…

4CPS-168 Effectiveness, quality of life and safety of atogepant for migraine prophylaxis

ejhpharm · abstract · 2026-03-18 · 7 matching annotations

94.4%

migraine CM Atogepant Neurology Department Ethics Committee

…ts calcitonin gene-related peptide (CGRP) receptors involved in migraine development.Aim and Objectives To evaluate atogepant effectiven…

4CPS-193 Descriptive real-world outcomes with aflibercept 8 mg/0.07 ml in wet age-related macular degeneration and diabetic macular oedema

ejhpharm · abstract · 2026-03-18 · 7 matching annotations

95.9%

diabetic macular oedema wet age-related macular degeneration DME AMD Aflibercept

…the treatment of wet age-related macular degeneration (AMD) and diabetic macular oedema (DME) in adults.Aim and Objectives To evaluate the use of aflib…

4CPS-238 Pharmaceutical care programme for patients undergoing allogeneic haematopoietic stem cell transplantation (PHARALLO): impact on clinical outcomes

ejhpharm · abstract · 2026-03-18 · 7 matching annotations

94.0%

aGVHD aGVHD-cumulative-incidence acute renal failure acute graft-versus-host disease aGVHD-related aGVHD-free European Society for Blood and Marrow Transplantation PHARALLO EBMT

…luded (37 intervention; 30 control).The cumulative incidence of aGVHD by day +100 was reduced by 13.4% in the intervention group (p=0…

4CPS-259 Impact of switching to biosimilar etanercept in rheumatoid arthritis patients followed in pharmaceutical consultations at a tertiary hospital

ejhpharm · abstract · 2026-03-18 · 7 matching annotations

96.7%

Rheumatoid arthritis RA Erelzi Benepali Enbrel

…Background and Importance Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic joint disease. Although…

4CPS-263 Evaluation of the efficacy and safety of anti-CGRP monoclonal antibodies (MABS) for the treatment of migraine at a central hospital

ejhpharm · abstract · 2026-03-18 · 7 matching annotations

99.3%

migraine Headache CGRP galcanezumab erenumab fremanezumab

…, anti-CGRP mAbs were associated with significant reductions in migraine frequency after 6 months. Galcanezumab showed the greatest mean…